Bio News
CAR-T cells targeting the two antigens DLL3 and CD56 completely eliminated tumors in a preclinical model of small cell lung cancer. Parallel 4-1BB signaling enhanced T-cell proliferation and persistence, overcoming limitations in treating solid tumors. Subsequent administration of DLL3 TriTCE increased CD8⁺ T-cell infiltration and confirmed an anticancer synergy.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
